| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US6485748 | COVIS | Once daily pharmaceutical tablet having a unitary core |
Dec, 2017
(6 years ago) | |
| US5916595 | COVIS | HMG co-reductase inhibitor |
Dec, 2017
(6 years ago) | |
| US6080778 | COVIS | Methods for decreasing beta amyloid protein |
Mar, 2018
(6 years ago) | |
Altoprev is owned by Covis.
Altoprev contains Lovastatin.
Altoprev has a total of 3 drug patents out of which 3 drug patents have expired.
Expired drug patents of Altoprev are:
- US6485748
- US5916595
- US6080778
Altoprev was authorised for market use on 26 June, 2002.
Altoprev is available in tablet, extended release;oral dosage forms.
Altoprev can be used as method of decreasing the production of a-beta using a composition which decreases blood cholesterol in patients at risk of or exhibiting symptoms of alzheimer's disease.
The generics of Altoprev are possible to be released after 23 March, 2018.
Drugs and Companies using LOVASTATIN ingredient
Market Authorisation Date: 26 June, 2002
Treatment: Method of decreasing the production of a-beta using a composition which decreases blood cholesterol in patients at risk of or exhibiting symptoms of alzheimer's disease
Dosage: TABLET, EXTENDED RELEASE;ORAL
ALTOPREV family patents
